The 340B Drug Pricing Program was originally constructed so safety-net health care facilities could stretch scarce resources in caring for low-income patients. However, the program has experienced ...
To add insult to injury, many hospitals that aggressively pursue unpaid medical bills profit from a federal drug discount program: the 340B Drug Pricing Program, which was established to help ...
Reforming the federal 340B Drug Pricing Program is a fast and efficient way to reduce drug costs and protect patients. These days, some 340B hospitals are taking advantage of low-income and uninsured ...
The federal 340B Drug Pricing Program ("340B Program") was created by Congress in 1992 through an amendment to the Public Health Service Act. [i] The program, which is administered by the Health ...
The 340B Drug Pricing Program was created to help low-income patients access medications at reduced costs. Ryan Augsburger argues that expanding the program could increase costs for employers and ...
The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...
Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known as the 340B drug pricing program — say they are closing in on legislation ...
On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...
The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...
Having served in both state and federal government, I know it is far too rare for elected officials to stand up to special interests with appropriate skepticism. That is why Michigan's House Speaker ...
Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results